New FDA approval marks new day for treating kids' brain cancer

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer. Sponsored Content Lower BMI, Raise ROI Presented by BuildMyHealth Reduce your dependence on an insurance-based practice or avoid the disruption in cash flow with the next Change Healthcare-like cyber attack! You can incorporate weight management into your practice and treat the underlying cause of whatever ailment brought your patient to your practice in the first place. All while potentially generating $300,000 in monthly recurring revenue. Learn more today! Secure Your Spot At INVEST 2024 Before It Is Too Late! Don't miss this opportunity to shape healthcare's future and forge valuable connections in Chicago, May 21-22.  ACT now - rates increase on Saturday! Get Your Ticket Now - Save $100

Featured News

Providence Ordered to Pay $200M for 'Systemic Wage Violations' More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that "sends a message to healthcare corporations," according to an attorney representing the workers. It's Time to Give Patients a Seat at the Table Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design. When Investment Rhymes with Canada Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception. Six Biopharma Companies to Watch at MedCity INVEST Pitch Perfect Contest The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, The companies will offer a window into some of the promising treatments under development such as different types of cancers to muscular dystrophy. Space is limited so register today!

Resources

MedCity Debunked: Change Healthcare Cybersecurity Attack, 23andMe Relevance and Startup Tips In this month's episode, we talk about the massive cyberattack at Change Healthcare that brought the healthcare payment processing clearinghouse to its knees. How were providers, patients, pharmacies, and health systems affected? We also talk about 23AndMe and its relevance in the marketplace. Finally, as a journalist and investor, we offer advice to startups on what is a turn-off for us.  Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe